Zydus files IND for diabetes/obesity compound in India
This article was originally published in Scrip
Zydus Cadila has filed an IND application for its GLP-1 agonist molecule (codenamed ZYD1) with the Drugs Controller General of India.
You may also be interested in...
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
Eisai and partner Sun to take lorcaserin off the Indian market. It remains to be seen whether the Japanese firm sees merit in pursuing a simmering patent infringement suit against Dr Reddy’s, which may need to review its own plans for lorcaserin.